🔗 Permalink

Inventor profile of:

Avi AVRAMOFF

City:

Haifa

Country:

Israel

Published Applications:

Last publication date:

2023-12-28

Top Assignees for applications by Avi AVRAMOFF

The entities that hold a legal rights for patent applications filed by inventor AVRAMOFF Avi:

DEXCEL PHARMA TECHNOLOGIES LTD. 7 Or- Akiva, Israel
Taro Pharmaceutical Industries Ltd. 5 Haifa Bay, Israel
DEXCEL LTD. 3 Hadera, Israel
DEXCEL PHARMA TECHNOLOGIES LTD. 2 JERUSALEM, Israel
TARO PHARMACEUTICALS INDUSTRIES LTD. 1 Haifa, Israel
Dexcel Pharma Technologies Ltd. 1 Hadera, Israel
DEXCELL LTD. 1 Hadera, Israel

Recent patent applications by AVRAMOFF Avi

Avi AVRAMOFF from Haifa, IL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-12-28

US20230414537A1

Human necessities

TOPICAL NAFTIFINE COMPOSITIONS

#2 | 2023-09-21

US20230293543A1

Human necessities

FENOLDOPAM TOPICAL FORMULATIONS FOR TREATING SKIN DISORDERS

#3 | 2023-09-07

US20230278956A1

Chemistry; metallurgy

PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF

#4 | 2023-08-10

US20230248641A1

Human necessities

TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS

#5 | 2023-02-23

US20230059107A1

Human necessities

STABLE TOPICAL COMPOSITIONS OF FENOLDOPAM

#6 | 2023-02-16

US20230051259A1

Chemistry; metallurgy

Preparation of Trifarotene and intermediates and polymorphs thereof

#7 | 2022-02-10

US20220040089A1

Human necessities

Stable topical compositions of fenoldopam

#8 | 2022-02-03

US20220031622A1

Human necessities

STABLE BENZIMIDAZOLE FORMULATION

#9 | 2022-01-20

US20220016028A1

Human necessities

Topical Montelukast formulations

#10 | 2021-12-23

US20210393613A1

Human necessities

Topical Montelukast formulations

#11 | 2021-08-05

US20210236423A1

Human necessities

Topical Montelukast formulations

#12 | 2020-07-30

US20200237651A1

Human necessities

TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS

#13 | 2020-02-04

US15585689

Human necessities

Topical montelukast for treatment of atopic dermatitis

#14 | 2019-10-31

US20190328746A1

Human necessities

Fenoldopam topical formulations for treating skin disorders

#15 | 2018-09-27

US20180271790A1

Human necessities

STABLE BENZIMIDAZOLE FORMULATION

#16 | 2016-06-09

US20160158148A1

Human necessities

Method for treating a periodontal disease

#17 | 2015-01-22

US20150024021A1

Human necessities

Method for treating a periodontal disease

#18 | 2014-10-23

US20140314846A1

Human necessities

MULTIPLE UNIT PHARMACEUTICAL FORMULATION

#19 | 2014-06-26

US20140178469A1

Human necessities

STABLE BENZIMIDAZOLE FORMULATION

#20 | 2012-04-26

US20120100199A1

Human necessities

Method for treating a periodontal disease

#21 | 2011-06-30

US20110159094A1

Human necessities

EXTENDED RELEASE COMPOSITIONS FOR HIGH SOLUBILITY, HIGH PERMEABILITY ACTIVE PHARMACEUTICAL INGREDIENTS

#22 | 2011-03-03

US20110052690A1

Human necessities

PROCESS FOR MANUFACTURE OF A MEDICAMENT WITH GRANULATION AND PAN COATING

#23 | 2011-03-03

US20110052648A1

Human necessities

ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES

#24 | 2011-02-17

US20110038933A1

Human necessities

STABLE BENZIMIDAZOLE FORMULATION

#25 | 2011-02-10

US20110033506A1

Human necessities

COMBINATION DOSAGE FORM OF LOW-DOSE MODAFINIL AND LOW-DOSE SILDENAFIL

#26 | 2010-11-25

US20100297226A1

Human necessities

MULTIPLE UNIT PHARMACEUTICAL FORMULATION

#27 | 2010-11-04

US20100278909A1

Human necessities

PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS

#28 | 2007-04-12

US20070082049A1

Human necessities

Extended release venlafaxine tablet formulation

#29 | 2007-03-22

US20070065513A1

Human necessities

Stable lansoprazole formulation

#30 | 2006-09-14

US20060205639A1

Human necessities

Pro-nanodispersion for the delivery of cyclosporin

#31 | 2006-03-16

US20060057204A1

Human necessities

Pharmaceutical compositions containing venlafaxine

InventorID:

814591 ⎘